Advertisement

Topics

Amgen Incorporated Company Profile

15:58 EDT 20th September 2017 | BioPortfolio

Over the past quarter century, Amgen has pioneered the methods by which human proteins that play a role in disease processes are identified, isolated, produced in quantity and used as therapeutics. Today, Amgenhas research programs in inflammation, metabolic disorders and osteoporosis, neurology, oncology and hematology. The company has R&D facilities in Thousand Oaks, CA; San Francisco, CA; Cambridge, MA; Cambridge, UK; Regensburg, Germany; and Seattle, WA.

With expertise in proteins, small molecules, antibodies, peptibodies, and nucleic acids, Amgen’s scientists can pursue the study of disease, choose the best target for a disease and then use the modality most likely to have an effect on that target. This approach positions Amgen as one of the only companies with capabilities across a range of modalities.

Mastering the tools of therapeutic development, as they emerge, is crucial to Amgen’s ongoing success. Accordingly, the company has invested at least 20 percent of product sales in research and development each year since 1994—a total of approximately $2.0 billion in 2004.

Location

One Amgen Center Drive
Thousand Oaks
CA
91320 1799
United States of America

Contact

Phone: 805 447 1000
Fax: 805 447 1010


News Articles [490 Associated News Articles listed on BioPortfolio]

Syngene expands Amgen collaboration as it recovers from fire incident

Syngene International is doubling the footprint of its research and development center following an expanded research collaboration with Amgen Inc. The Indian contract research organization inaugurate...

Amgen Remains A Standout Among Biotechs

Amgen's Repatha is believed to have potential sales of $2 billion by 2020

Amgen To Present At The UBS Global Life Sciences Conference

THOUSAND OAKS, Calif., May 16, 2013 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will participate in the UBS Global Life Sciences Conference on Tuesday, May 21, 2013, at the Sheraton New York Times Square...

Amgen up as Xgeva closes in on expanded indication

US biotech Amgen closed 1.6% up on Monday at $165.09 after news of further progress relating to its monoclonal…

Amgen-Aktie: Eines der besten Signale überhaupt - Chartanalyse

Düsseldorf - Amgen-Chartanalyse von HSBC Trinkaus & Burkhardt: Die Analysten von HSBC Trinkaus & Burkhardt nehmen in einer aktuellen Aktienanalyse die Aktie des Biotechkonzerns Amgen Inc. (ISIN: US.....

The Price Is Right: Amgen Defends Repatha At $9,669 Against More Critics

Using a higher event rate typical of real-world, high-risk CV patients, Amgen asserts Repatha is cost effective at $9,969, the...   

Amgen löst keine Begeisterungsstürme aus! - Aktienanalyse

Rye - Amgen-Aktienanalyse der Analystin Jing He von Gabelli & Company: Jing He, Aktienanalystin bei Gabelli & Company, empfiehlt im Rahmen einer Aktienanalyse die Aktien des Biotechkonzerns Amgen I...

GNS Healthcare Adds $6M, Led by Amgen, for Machine Learning Tech

The investment arm of biotech giant Amgen has led a new $6 million round of funding in GNS Healthcare, CEO Colin Hill tells Xconomy. Amgen Ventures’ new investment is a part of the company’s Serie...

PubMed Articles [5 Associated PubMed Articles listed on BioPortfolio]

Letter--The Authors Respond.

None of the authors of this study are involved in financial or personal relationships with agencies, institutions, or organizations that inappropriately influenced the statistical analysis plan or int...

Distribution of RANK and RANK Ligand in Normal Human Tissues as Determined by an Optimized Immunohistochemical Method.

The expression and tissue distribution of RANK (Receptor Activator of Nuclear Factor κ B) and RANK Ligand (RANKL) are of critical interest in relation to efficacy and safety of antibodies against RAN...

AERODYNAMIC PROPERTIES AND IN SILICO DEPOSITION OF MELOXICAM POTASSIUM INCORPORATED IN A CARRIER-FREE DPI PULMONARY SYSTEM.

Dry powder inhalers (DPIs) have been among the fastest developing inhaler forms in the past decades. Researches are focusing on the formulation of carrier-free powders to obtain a higher deep-lung dep...

Patent trend and competitive analysis of cancer immunotherapy in the United States.

Immunotherapy has brought high hopes for cancer treatment, and attracted tremendous resources from the biopharmaceutical community. Here we analyze cancer immunotherapy-related patents granted by the ...

Evolocumab for Treating Primary Hypercholesterolaemia and Mixed Dyslipidaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.

As part of its single technology appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clini...

Clinical Trials [16 Associated Clinical Trials listed on BioPortfolio]

A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin

The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen,) based on maintenance of hemoglobin (Hb) levels and s...

An Open Label Treatment Extension Study of AMG 706

This is an extension study to provide ongoing treatment with AMG 706 monotherapy for subjects with solid tumors who have completed the planned duration of AMG 706 treatment on a separate A...

Amgen Megakaryopoiesis Protein 2 (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP)

The purpose of this study is to assess the safety, tolerability, and utility of AMG 531 unit dosing (µg) in thrombocytopenic subjects with ITP.

Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation

The purpose of this study is to collect local laboratory data on immunoreactive parathyroid hormone (iPTH), calcium and phosphorus levels and estimated glomerular filtration rate (GFR) at ...

Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma

5-Drug Combination Chemotherapy with Hematologic Toxicity Attenuation. EPOCH: Etoposide, VP-16, NSC-141540; Prednisone, PRED, NSC-10023; Vincristine, VCR, NSC-67574; Cyclophosphamide, CTX...

Companies [80 Associated Companies listed on BioPortfolio]

Amgen, Inc.

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bri...

Amgen Inc.

Amgen discovers, develops, manufactures and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bri...

Amgen

The Amgen Foundation (www.amgen.com/citizenship/overview.html) seeks to advance science education; improve patient access to quality care; and strengthen the communities where Amgen staff members live...

Amgen AB

Amgen är ett världsledande bioteknologiskt läkemedelsföretag. Genom vetenskapliga upptäckter och innovationer har företaget under 25 års tid bidragit till att radikalt förbättra människors l...

Amgen Inc

Amgen is a leading human therapeutics company in the biotechnology industry. For 25 years, the company has tapped the power of scientific discovery and innovation to dramatically improve people’s li...

More Information about "Amgen Incorporated" on BioPortfolio

We have published hundreds of Amgen Incorporated news stories on BioPortfolio along with dozens of Amgen Incorporated Clinical Trials and PubMed Articles about Amgen Incorporated for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Amgen Incorporated Companies in our database. You can also find out about relevant Amgen Incorporated Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Neurology - Central Nervous System (CNS)
Alzheimer's Disease Anesthesia Anxiety Disorders Autism Bipolar Disorders Dementia Epilepsy Multiple Sclerosis (MS) Neurology Pain Parkinson's Disease Sleep Disorders Neurology is the branch of me...


Corporate Database Quicklinks



Searches Linking to this Company Record